Reuters logo
BRIEF-Santhera's Raxone designated promising innovative medicine in UK
December 23, 2016 / 6:19 AM / a year ago

BRIEF-Santhera's Raxone designated promising innovative medicine in UK

Dec 23 (Reuters) - Santhera Pharmaceuticals Holding AG :

* Raxone designated promising innovative medicine and suitable candidate for further evaluation under U.K. Early Access To Medicines Scheme (EAMS) for treatment in duchenne muscular dystrophy Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below